S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma
Sponsor: National Cancer Institute (NCI)
This PHASE2 trial investigates Pancreatic Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 8 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Ann Arbor, United States, Atlanta, United States, Billings, United States, Biloxi, United States, Boston, United States, Cincinnati, United States, Cleveland, United States, Columbus, United States, Dallas, United States and 46 more location s